AWM
ACAD icon

AE Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

AE Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,282
Closed -$412K – 1149
2023
Q4 		$412K Buy
+15,282
New +$365K ﹤0.01% 1555

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AE Wealth Management's ACAD Position: Q1 2024 in Review

AE Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 15,282 shares — an estimated $412K sold.

AE Wealth Management first reported a position in ACAD in Q4 2023 and held it in 1 quarter. The position peaked at $412K in Q4 2023. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • AE Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • AE Wealth Management sold 15,282 Acadia Pharmaceuticals shares in Q1 2024, an estimated $412K.
  • AE Wealth Management first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • AE Wealth Management's Acadia Pharmaceuticals position peaked at $412K in Q4 2023.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on AE Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.